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ABSTRACT Once overlooked, awareness of nontuberculous mycobacterial pulmonary disease (NTM-
PD) is rapidly rising, in line with increasing prevalence worldwide. The European Respiratory Society
(ERS) International Congress 2019, held in Madrid, Spain, provided a platform for invigorating
discussions and exciting new research in the field. This article explores approaches being taken to combat
NTM-PD with a focus not only on novel prevalence and risk factor data, but also on emerging
antimicrobials and their routes of delivery, and other potential treatment options in early clinical
development.
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Emerging research provides an insight into future treatment approaches for nontuberculous
mycobacterial pulmonary disease (NTM-PD) – a serious, chronic, infectious disease that often
presents in patients with underlying respiratory disease https://bit.ly/31spZpE
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Nontuberculous mycobacterial pulmonary disease (NTM-PD) has a devastating impact on patients [1],
with a poor long-term outcome. Global estimates of 5-year all-cause mortality are high, with estimates
ranging from 25% to 40%, and is not substantially improved by current treatment [2–5]. The condition
typically occurs as a comorbid infection in patients with underlying respiratory disease, such as COPD,
bronchiectasis and cystic fibrosis (CF) [6–8]. Patients often face a lengthy time to diagnosis, or their
disease may be misdiagnosed as symptoms which can appear to be part of the underlying lung disorder
rather than a separate infection [9]. The heterogeneity of presentation and underlying pulmonary disease
means that care for patients with NTM-PD is often fragmented.
NTM-PD is steadily increasing in prevalence worldwide [10] and while awareness is rising, it remains
suboptimal. The evidence base for NTM-PD investigation and management is limited compared with
other respiratory disorders. In line with the increasing prevalence, however, there is renewed interest in
NTM-PD and increasing research activity. This was reflected at the 2019 European Respiratory Society
(ERS) Congress in Madrid, Spain, where several high-profile symposia and abstract sessions focussing on
NTM-PD were scheduled. Sessions addressed the clinical characteristics of the disease, its incidence and
prevalence, its management (including guideline-based treatment (GBT) and treatment outcomes) and
potential new therapies on the horizon for this debilitating disorder. Here we present some of the
highlights and novel data presented at the ERS Congress in 2019.
Approach to evaluating the presence of NTM-PD at ERS 2019
In order to explore NTM-PD content at the ERS 2019 Congress a committee chaired by Professors
Chalmers and Rohde was convened. A review of the ERS 2019 Congress programme identified 110
sessions (abstracts and posters, symposia and speaker sessions) covering NTM-PD. Of the 110 identified
sessions 24 (13 thematic posters; seven poster discussions; and four oral presentations) were prioritised by
Professors Chalmers and Rohde for attendance by a committee member and then further review by all
authors. Prioritised sessions covered the topics of diagnosis, prevalence, risk factors and treatment. Each
NTM-PD session was presented to the committee for discussion and a selection for further inclusion in a
publication was agreed. Given the nature of abstracts and symposia, content was reviewed subjectively, and
those considered most interesting or robust were included.
Epidemiology and microbiology
Determining and understanding the causative agent for infection in NTM-PD can be difficult, as a result
of widely varying epidemiological characteristics, considerable heterogeneity in the bacteria involved, and
regional variations in species prevalence [10–13]. Individuals at risk of NTM-PD are diverse and include
patients who are immunosuppressed [14, 15] and those with underlying diseases [16, 17].
Many NTM-PD studies are retrospective or observational and may be based on microbiological isolates.
Non-tuberculous mycobacteria (NTM) are frequent environmental contaminants; therefore, the presence
of an isolate in sputum culture does not confirm the presence of active infection. The American Thoracic
Society/Infectious Diseases Society of America (ATS/IDSA) consensus criteria, published in 2007, for
active infection requires the presence of clinical, radiological and microbiological evidence of NTM-PD.
Our understanding is insufficient to enable linking of isolate or genomic information to causative agents
and their virulence in causing disease requiring treatment. Genomic speciation for NTM has been
undertaken [18] and it has been confirmed that, of the >200 species, the most common disease-causing
isolates are Mycobacterium avium complex (MAC), Mycobacterium kansasii and Mycobacterium abscessus
complex; however, it remains unclear how these isolates correlate with disease. Recent studies from Europe
have begun to investigate the link between individual isolates and clinical disease. VANDE WEYGAERDE et al. [19]
demonstrated that MAC, Mycobacterium gordonae and Mycobacterium xenopi were the most frequently
isolated species in Belgian centres. M. abscessus, Mycobacterium malmoense and MAC were most
frequently associated with clinical disease. In another study, Mycobacterium intracellulare was the most
frequently isolated species but isolation of bacteria did not correlate with active infection [20]. Data from
the European Bronchiectasis Registry (EMBARC) explored speciation in active disease and identified MAC
as the most widely isolated organism derived in patients, followed by M. abscessus, Mycobacterium
fortuitum, M. kansasii and M. malmoense [21]. The results of these studies confirm the diversity of species
isolated in different disease cohorts. The major challenge remains to identify when a species is causing
progressive disease and requires treatment [21].
While MAC is commonly isolated, infection does not necessarily result in pulmonary disease or the need
for treatment. However, two radiological patterns have been identified in patients with pulmonary disease
caused by MAC, each with differing disease outcomes [22]: fibrocavitary disease is more common in men
with chronic pulmonary disease, while nodular bronchiectatic disease is usually associated with better
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outcomes and is more frequently found in post-menopausal women. A more recent study has also
demonstrated that the presence of cavitation, however limited or small, is associated with worse outcomes,
even if the predominant presentation is nodular bronchiectatic disease [22, 23]. For this reason, cavitation
is considered a strong indication for initiating treatment in NTM-PD. The collated understanding of
organism speciation, patient phenotype and disease outcomes therefore continues to evolve.
Testing for NTM can be costly, and there is not necessarily a correlation between the presence of NTM in
respiratory cultures and active infection. Identifying individuals with a higher potential risk of NTM
infection could allow for more targeted testing and could be useful for patients, clinicians and healthcare
systems. Across the studies presented at ERS 2019, key risk factors for isolation of NTM were identified as
bronchiectasis [20, 21]; immunosuppression [24]; and older age and the presence of specific radiographic
characteristics [25]. Inhaled corticosteroid use has also been suggested as a risk factor for development of
NTM in patients with underlying pulmonary disease [14, 26, 27]. In the future, a thorough understanding
of patient phenotypes will be essential, as there is no standardised approach to testing in Europe.
Thresholds for who is tested differ between institutions, with some testing all patients annually, while
others will test those who fit the criteria for clinical suspicion (low body mass index, female sex, persistent
cough) or who have frequent exacerbations.
As previously mentioned, the identification of active NTM is based on the ATS/IDSA criteria published in
2007, requiring clinical symptoms, radiological changes and microbiological criteria [28]. Patients meeting
diagnostic criteria for NTM should undergo treatment, rather than watchful waiting, but the risks posed
by NTM infection to the individual patient and the burden of treatment must be considered; tools that
can identify the patients who would benefit most from therapy are eagerly anticipated.
Treatment options: optimising current approaches
While the effect of NTM-PD on patients’ lives can be chronic and devastating [29], the impact of
treatment can also be punishing as therapy is lengthy, involves complicated dosing schedules and may
result in toxic adverse events (AEs) [9]. Treatment of NTM-PD requires a combination of oral, parenteral
and nebulised antibiotics for an extended duration (18–24 months and for at least 12 months after
achievement of sputum negativity) [28–31]; this may lead to poor patient adherence. AEs resulting from
therapy are common and are a key reason for early treatment cessation, which is associated with treatment
failure [32]. In a study conducted across three centres in Belgium of patients with NTM-PD caused by
MAC, treatment adherence was low [33]. Of 60 patients receiving at least three drugs including a
macrolide (in accordance with ATS/IDSA 2007 recommendations), just over half (33 out of 60) completed
12 months of therapy. Approaches to improve adherence and patient outcomes have been attempted, and
a retrospective study presented at ERS 2019 explored the potential of using high-dose drugs with a
reduced frequency of treatment administration. In this small cohort study comparing daily versus twice
weekly therapy, the burden of AEs was reduced in the patients receiving less frequent treatment, but the
study was too small to draw firm conclusions [34]. Therapy three times per week is also accepted for mild
MAC disease, with similar treatment outcomes to daily therapy. Therefore, further testing of twice weekly
therapy is of interest to reduce treatment burden. There remains a need for less toxic, more effective
antibiotic therapies that do not need to be administered intravenously [33], and an improved
understanding of which patients should receive and will benefit most from therapy [35].
Guidelines for treating NTM-PD are available from the ATS/IDSA [28], with an update due for
publication in 2020. The joint 2007 ATS/IDSA NTM guidelines [28] recommend a minimum evaluation
for patients with suspected NTM of a chest radiograph or chest high-resolution computerised tomography
scan, plus at least two separate expectorated sputum samples or positive culture results from at least one
bronchial wash or lavage, and exclusion of tuberculosis and lung cancer. Newer guidelines from the British
Thoracic Society are also in place [36], with specific guidelines for patients with CF associated NTM [37].
Treatment success with 2007 ATS/IDSA GBT is often suboptimal; success rates (defined as culture
conversion) for M. abscessus are ∼25–60% [38]. Success rates for MAC infection are higher, ranging
between roughly 50% and 90%, but there is a relapse rate (defined as recurrence of MAC infection from
the same MAC strain rather than reinfection by a different strain) of 4–12%. Results of a survey in the
USA also suggested that adherence to GBT by clinicians was low [39]. European data are comparable;
treatment practices as of 2017 were highly heterogeneous, with only 13% of patients eligible for therapy
receiving the regimen recommended by ATS/IDSA 2007 recommendations [40].
Even when treatment is undertaken in line with guidelines, success is not guaranteed. In a Turkish
single-centre study conducted over 10 years [41], 889 patients with NTM-positive sputum samples were
identified. Of these, 102 (11.47%) patients received 2007 ATS/IDSA GBT with just 40 patients (39.21%)
achieving treatment success. Recurrent disease was apparent in three patients (2.94%) and 24 patients
(23.52%) had ongoing disease. Although the definition of treatment success and antibiotic regimens were
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not clearly defined, these data highlight that treatment success with 2007 ATS/IDSA GBT is suboptimal,
and support results of meta-analyses suggesting a success rate for treating MAC with GBT ranging from
32% to 65% [42]. For M. abscessus treatment, the success rate was 45.1% with significantly greater success
being observed among patients infected with M. abscessus subspecies massiliense compared to those
infected with subspecies abscessus (81.4% versus 33.5%) [43].
Interpreting treatment success data is difficult in the absence of prospective studies that explore treatment
outcomes according to the duration of therapy. Current recommendations for treatment length are
determined by clinical experience rather than evidence-based data and, as such, understanding how long
to treat patients remains an unmet clinical need.
Treatment options on the horizon
Given the dual issues of adherence, from the perspective of both clinician and patient, and efficacy of
available treatment options, there is an urgent need for new approaches and therapies for NTM-PD caused
by MAC and M. abscessus.
Nitric oxide (NO) is a naturally produced gas that plays a role in host innate defence mechanisms against
various microorganisms including mycobacteria [44]. An abstract presented at ERS 2019 investigated the
role of nitric oxide in treatment of M. abscessus. CHAU et al. [45] performed an in vitro study in which
perfusion of M. abscessus strains with nitric oxide in combination with clofazimine and amikacin resulted
in a greater reduction in M. abscessus bacterial load, compared with nitric oxide or clofazimine alone.
These data are interesting and offer a new approach to treatment, although it is unclear whether in vitro
findings will translate to animal models or human studies. Encouraging data are emerging that suggest a
role for nitric oxide in the treatment of M. abscessus infection. In one study, compassionate adjunctive
inhaled nitric oxide in two CF patients with M. abscessus infection demonstrated significant improvements
in bacterial load [46], an observation supported by further data from the same group in a prospective pilot
study [47]. In this study, nine patients with CF and M. abscessus experienced increases in both forced
expiratory volume in 1 s (FEV1) and 6-min walking distance (6MWD) results from baseline as well as
reductions in bacterial load [47]. While this study was not powered for significance and no statistics were
presented, and culture conversion was not achieved, three out of nine patients did experience at least one
negative culture during the study, suggesting that future research of nitric oxide against M. abscessus is
warranted. It is also unclear from current data how nitric oxide might impact on M. abscessus sequestered
within biofilms or macrophages, and what effect it may have alone or in combination with amikacin or
clofazimine. A generator of nitric oxide from ambient air is currently being explored commercially for the
treatment of NTM-PD [48] and it will be interesting to see the potential impact of this therapy on the
condition in the next few years.
Another study presented at ERS 2019 explored the combination of amikacin and clofazimine on MAC
infection [49]. In this study, patients were treated with either rifampicin/ethambutol/macrolide (n=25)
or rifampicin/ethambutol/macrolide plus amikacin/clofazimine (n=19). Whilst combination therapy of
rifampicin/ethambutol/macrolide plus amikacin/clofazimine demonstrated a trend towards better
microbiological cure rates than rifampicin/ethambutol/macrolide (74% versus 52%) this was not
statistically significant (p=0.337). A trend towards a faster time to sputum conversion (15 weeks versus
18 weeks) was also observed. It will be interesting to see how these data translate to randomised controlled
clinical studies, ideally with comparator arms of amikacin and clofazimine alone to determine the impact
of the combination.
Long-term data were presented from the CONVERT (Amikacin Liposome Inhalation Suspension (ALIS) for
Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex) study by GRIFFITH et al. [50],
which follow on from the original study published in 2018 [51]. In the study, patients with confirmed
amikacin-susceptible MAC received ALIS plus 2007 ATS/IDSA recommended GBT (n=224) or GBT alone
(n=112). Culture conversion by month 6 was achieved by 65 out of 224 (29%) patients treated with ALIS
plus GBT compared with 10 out of 112 (9%) patients receiving GBT alone [51]. The recently presented data
demonstrated that culture conversion was sustainable (defined as culture negative for all cultures taken from
conversion through to the end of treatment) and durable (defined as culture negative in the absence of
treatment for 3 months). At the end of treatment (up to 12 months post-conversion), 80% (52 out of 65) of
patients treated with ALIS plus GBT who had achieved culture conversion remained culture negative
compared with 30% (three out of 10) receiving GBT alone [50]. 3 months post treatment, durability of
response was 63% (41 out of 65) of patients who received ALIS plus GBT and 0% (0 out of 10) of patients
who had received GBT alone, although no statistics were reported. Tolerability of treatment and side-effects
for extended antibiotic therapy were comparable with those presented in the original study [51]. There were
no differences between treatment arms in terms of change in 6MWD results from baseline to month 8
(p=0.84). The CONVERT study was conducted in patients with refractory NTM-PD; in future, it will be
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important to evaluate longer-term follow-up results to explore the durability of culture conversion and
reinfection rates. The low response rates in the GBT arm also emphasise the importance and challenging
nature of refractory MAC disease. It will be interesting to explore further the impact of ALIS in patients as a
strategy to prevent the development of refractory disease and to study its efficacy in patients newly
diagnosed with NTM-PD caused by MAC.
Future avenues for study
As NTM-PD gains more interest from the research community, some new and attractive avenues are
opening. To optimise treatment and outcomes for patients with this condition, it will be valuable to
understand the link between isolates, pathogenicity and clinical relevance through the design of
prospective studies that explore organisms and the trajectory of disease for individuals. These studies could
investigate the impact of isolates on disease progression using prognostic factors such as change in lung
function, body mass index and radiological changes/deterioration. It will also be important to understand
the impact of NTM-PD and its treatment on individual patients.
From a clinical trial perspective, end-points that have an impact on patients’ lives, including functional
outcomes that can be applied effectively in studies, are needed [28, 52, 53]. Traditionally, the 6MWD test
has been used as a measure of functional status in NTM disease. However, distance walked seldom
correlates with disease severity and even very sick patients may be able to reach normal distances in the
allotted time, leading to suggestions by the US Food and Drug Administration that it is a poor functional
outcome [54]. In some studies where microbiological and culture conversion outcomes have been good,
similar changes in quality of life measures have not been seen [51]. Other functional outcomes that could
be used include improved body mass index and weight gain, as well as improvements in quality of life
demonstrated using rating scales such as the St George’s Respiratory Questionnaire and the Quality of Life
Questionnaire-Bronchiectasis for which an NTM-PD module has recently been published [55]. An
appraisal of these and other new functional outcomes is long overdue to provide clinical end-points that
move beyond culture conversion and focus on patients. A disease-specific patient-reported outcome
measure for NTM would be of significant value.
Patient goals for treatment need to be considered. These are diverse and include parameters such as
fatigue, cough or breathlessness; such end-points are individual to patients and may be difficult to
extrapolate to the clinical study setting. Greater emphasis on functional outcomes and how these change
with treatment in NTM disease is clearly needed. As such, it will be important to develop and validate
quality of life measures that can discriminate meaningfully between treatment success and failure.
Increasing understanding across Europe
For many years the study of NTM within Europe was neglected with little understanding of the
epidemiological perspective of NTM species. One of the first publications to attempt to study NTM across
multiple European countries was conducted by HOEFSLOOT et al. [56] and reported heterogeneity of NTM
species causing clinically relevant disease across Europe. Since then, a range of initiatives have sought to
increase awareness of NTM epidemiology, impact and treatment including NTM-NET, an international
network of clinicians and scientists to promote clinically oriented research in NTM, and the European
Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC), which operates a European
NTM registry alongside the successful European Bronchiectasis Registry in partnership with NTM-NET.
European educational and advocacy initiatives have been developed, leading to the first NTM workshop
held in Vienna in 2019 and the World Bronchiectasis and NTM conference held in Washington DC in
2018 and due to take place in Barcelona in 2020. These events have brought together hundreds of
interested clinicians and scientists to stimulate collaborations and improve practice. Despite European
efforts to increase awareness of NTM and to improve treatment in line with guideline recommendations,
there is still some way to go. Even in 2020, a survey by NTM-NET [57] has shown that patients with
bronchiectasis (those at highest risk of contracting NTM [58, 59]) are not being routinely tested for NTM;
this includes patients being considered for macrolide monotherapy, despite strong recommendations from
2020 guidelines that NTM testing should be conducted before treatment initiation [60]. Importantly,
among surveyed clinicians there was relatively high (>60%) understanding of the mortality and morbidity
burden of NTM. NTM-PD, as demonstrated by its presence at the ERS Congress in 2019, is now out of
the shadows.
Conclusions
NTM disease is a chronic condition that is difficult to treat and devastating for patients. Individuals at
particular risk of infection are those with underlying respiratory disease or who are immunocompromised.
However, a patient phenotype to guide treatment decisions that balances risks and benefits is still needed.
It is also likely that the true prevalence of NTM in patients with pulmonary disease is underestimated
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given the lack of standard testing for NTM as part of routine microbiological investigations in patients
with pulmonary disease. Therefore, further prospective studies of the prevalence of NTM in pulmonary
diseases and the identification of further risk factors for colonisation or infection of the lung are necessary.
As current therapies for NTM-PD are punishing for patients and have suboptimal outcomes, new
approaches and treatment options are required. At ERS 2019, strategies discussed included flexible dosing
schedules, new drug combinations in the form of amikacin and clofazimine, and data for the inhaled
delivery of ALIS (box 1).
It is encouraging to see the field of NTM-PD expanding, with increasing interest, research and new
publications. It is clear that the battle against NTM will need to take several fronts, from science to clinical
management and increased awareness. The hope is that future research and the data generated will
translate into improved and optimised patient care.
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